Canaccord Genuity analyst John Newman has maintained their bullish stance on REGN stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
John Newman’s rating is based on several positive indicators for Regeneron. The company reported strong sales for EYLEA and EYLEA HD, which exceeded expectations despite facing certain challenges, indicating a potential stabilization of the EYLEA franchise. Additionally, Regeneron is heavily investing in its in-house assets, particularly Lynozyfic for multiple myeloma, which is expected to significantly contribute to long-term revenue growth.
Furthermore, the growth in Dupixent revenues, driven by recent label expansions and its safety advantage over emerging competitors, further strengthens Regeneron’s market position. The company’s weight-loss program also shows promise, potentially offering a unique approach to addressing obesity-related comorbidities. These factors, combined with the anticipation of resolving delayed catalysts and the potential success of upcoming trials, support the Buy rating and the $850 price target for Regeneron.